European LeukemiaNet
SHORTPROTOCOL
AIDA2009

Scientific Title	Recommendations for risk adapted treatment of acute promyelocytic leukemia in the AML-SAL-Study group - an observational study -
Short Title	AIDA2009
Id KN/ELN	LN_SAL_2010_370
Trialgoup	SAL
Type of Trial	multicentric
Disease	Acute myeloid leukemia(AML) FAB M3 (APL)
Stage of Disease	de novo/non-treated
Aim	- registration of number and basic characteristics of patients, remission rates, toxicity and survival - long term remission, tolerance
Outcomes	- CR-Rate, Remissionsdauer, Überleben CR rates, duration of remission, survival (Primary Outcome) - Toxizität toxicity
Inclusion Criteria	- Diagnosis of acute promyelocytic leukemia, based on morphological result and confirmatory cytogenetic/molecular finding of t(15;17) and/or PML/RAR - no contraindication for chemotherapy - informed consent
Exclusion Criteria	- contraindications for intensive chemotherapy, e.g. cardial co-morbidities
Age	>= 18 years
Status	Closed
start of Recruitment	19.10.2009
Recruiting countries	Germany
Scientific Contact (WHO)	Platzbecker, Prof. Dr. med., Uwe Universitätsklinikum Dresden Medizinische Klinik und Poliklinik Fetscherstr. 74 01307 Dresden Tel: +49 (0)351 4582583 Fax: +49 (0)351 458-5362 Email: Uwe.Platzbecker@uniklinikum-dresden.de
Contact Person	**principal investigator** Platzbecker, Prof. Dr. med., Uwe Tel: +49 (0)351 4582583 Fax: +49 (0)351 458-5362 Email: Uwe.Platzbecker@uniklinikum-dresden.de **Study Centre** Peschel, Katrin Tel: +49 (0)351 458 5222 Email: katrin.peschel@uniklinikum-dresden.de
Remark	ATRA and chemotherapy followed by Maintenance therapy with chemotherapy and ATRA; www.sal-aml.org